指南与共识细菌感染、耐药与抗菌药物医院感染防控

儿童发热性中性粒细胞减少伴肾脏清除增强时万古霉素群体药代动力学及新剂量推荐

Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations.
指南 / 共识 · J Antimicrob Chemother · 2021-01-01

该研究基于165例儿童患者和276个万古霉素血清浓度,采用二室模型进行群体药代动力学分析,发现年龄、体重、eGFR和发热显著影响万古霉素清除。模拟显示现有剂量方案达标率差,6月龄至6岁伴ARC患儿需初始剂量较现行指南提高35%-65%,并据此提出基于eGFR、年龄、体重和体温的给药策略。

要点

  • ARC在HSCT后发热性中性粒细胞减少患儿中常见,显著增加万古霉素清除。
  • 6月龄至6岁伴ARC患儿初始万古霉素剂量需较现行指南提高35%-65%。
  • 新剂量策略基于eGFR、年龄、体重和体温制定。

核心结论

  • ARC在HSCT后发热性中性粒细胞减少患儿中频繁出现,导致万古霉素清除显著增加,现行剂量方案达标率差。
  • 提出基于eGFR、年龄、体重和体温的万古霉素给药策略。

研究设计与样本

  • 基于二室模型结构的群体药代动力学分析,采用非线性混合效应模型方法。
  • 纳入165例儿童患者和276个万古霉素血清浓度。
  • 进行蒙特卡洛模拟,以MRSA在MIC为1 mg/L时AUC在400 mg·h/L至650 mg·h/L之间为目标达标分析。

主要发现

  • 年龄、体重、eGFR和发热(≥38.0°C)被确定为显著影响万古霉素清除的因素。
  • 人群eGFR中位数为143 mL/min/1.73 m2,34%的患者eGFR≥160 mL/min/1.73 m2,可能归类为ARC。
  • 模拟显示现行剂量推荐达标率差。
  • 6月龄至6岁伴ARC患儿需初始万古霉素剂量较现行指南提高35%-65%。

关键数值与推荐

  • 目标AUC范围为400 mg·h/L至650 mg·h/L(MRSA,MIC=1 mg/L)。
  • ARC可能分类标准为eGFR≥160 mL/min/1.73 m2。
  • 6月龄至6岁伴ARC患儿初始剂量需较现行指南提高35%-65%。

临床怎么用

  • 对HSCT后发热性中性粒细胞减少患儿应评估eGFR以识别ARC。
  • 6月龄至6岁伴ARC患儿可考虑初始万古霉素剂量较现行指南提高35%-65%。
  • dosing策略应综合eGFR、年龄、体重和体温制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purpose of this study was to evaluate the influence of augmented renal clearance (ARC) on vancomycin clearance and provide dosage recommendations for paediatric patients with febrile neutropenia following HSCT. METHODS: A population pharmacokinetic analysis was performed based on a two-compartment model structure using a non-linear mixed-effect modelling approach. Monte Carlo simulations were conducted as a target attainment analysis of AUC between 400 mg·h/L and 650 mg·h/L for MRSA at an MIC of 1 mg/L. RESULTS: A total of 165 paediatric patients and 276 vancomycin serum concentrations were analysed in this study. Age, body weight, estimated glomerular filtration rate (eGFR) and fever (≥38.0°C) were identified as factors that significantly influenced vancomycin clearance. The median eGFR of the population was 143 mL/min/1.73 m2 and 34% of patients showed an eGFR ≥160 mL/min/1.73 m2, which may be classified as ARC. Our simulations showed that current dosing recommendations result in poor target attainment. In particular, children aged 6 months old to 6 years old with ARC require an initial vancomycin dose up to 35%-65% higher than the current dosing guidelines. CONCLUSIONS: ARC is frequently observed in paediatric patients with post-HSCT febrile neutropenia, resulting in a significant increase in vancomycin clearance. We propose a vancomycin dosing strategy for children with febrile neutropenia following HSCT based on eGFR, age, weight and body temperature.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Shimamoto Y, Verstegen RHJ, Mizuno T, et al. Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations. J Antimicrob Chemother. 2021. PMID: 34480578. doi:10.1093/jac/dkab302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。